Amyotrophic Lateral Sclerosis (ALS) Market: Competition, Size and Industry Growth Analysis by 2028 - TechSci Research

Introduction

The Global Amyotrophic Lateral Sclerosis (ALS) Market, valued at USD 0.5 billion in 2022, is projected to exhibit substantial growth with a CAGR of 5.00% through 2028, as per TechSci Research’s comprehensive report. Collaborations and partnerships among industry leaders, aimed at leveraging diverse expertise, are driving this anticipated market expansion.

Market Drivers: Fast-Tracking and Regulatory Incentives

Fast-tracking and regulatory incentives play pivotal roles in propelling the ALS market forward. ALS therapies receiving priority review status benefit from expedited timelines, encouraging pharmaceutical entities to develop treatments more efficiently. ALS, classified as an orphan disease in multiple regions, entices companies with reduced regulatory fees, tax credits, and extended market exclusivity, fostering economic viability for ALS drug development. These incentives also attract research funding from public and private sources, encouraging innovation in ALS research and the development of novel therapies. The acceleration of new ALS treatments benefits patients, providing quicker access to potentially life-changing therapies.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on “Amyotrophic Lateral Sclerosis (ALS) Market.” – https://www.techsciresearch.com/report/amyotrophic-lateral-sclerosis-als-market/19774.html

Who will benefit from this Report:

Pharmaceutical Companies: Gain insights into regulatory influences, fostering an environment conducive to innovation.
Investors and Grant Agencies: Understand the impact of regulatory incentives on funding ALS research projects.
Regulatory Bodies: Recognize the significance of fast-tracking in expediting treatments for ALS patients.
Healthcare Providers: Access information on emerging therapies and their impact on patient care.

Understanding ALS: Challenges and Impact

ALS, known as Lou Gehrig’s disease, is a progressive neurological disorder leading to the degeneration of nerve cells controlling voluntary muscle movements. Its hallmark features include muscle twitching, stiffness, and declining arm and hand strength due to muscle atrophy.

Recent Treatment Approvals and Research Advances

In April 2023, Biogen Inc. received FDA approval for QALSODY, a treatment for ALS in adults with a specific gene mutation (SOD1). This accelerated approval is based on observed reductions in plasma neurofilament light chain (NfL) levels in treated patients. Confirmation of clinical benefits will depend on subsequent trials, such as the Phase 3 ATLAS study for tofersen in presymptomatic SOD1-ALS individuals. Neurofilament proteins serve as crucial markers for neurodegeneration in ALS.

Challenges in the ALS Market

The limited patient population presents a significant hurdle in the ALS market. Being a rare disease, ALS affects a small number of individuals, making it economically challenging for pharmaceutical companies to invest in research and drug development. The constrained market size for ALS-related treatments may discourage resource allocation due to potentially lower returns on investment compared to more prevalent diseases. Clinical trials, regulatory approvals, and post-marketing surveillance become more challenging due to difficulties in recruiting sufficient participants, further increasing development costs. Balancing research costs with patient affordability in a limited market poses a pricing challenge for pharmaceutical companies.

Segmentation and Regional Insights

The Global ALS Market is segmented based on Drug Type, Treatment Type, End User, and Region. Notably, Edaravone (Radicava) is a medication specifically approved for ALS treatment, administered intravenously to slow disease progression and enhance patients’ quality of life.

Regional Dominance: North America

North America holds the largest share in the Global ALS Market. ALS advocacy groups in this region have effectively raised awareness, funded research, and advocated for improved patient care. The regulatory environment in the United States supports fast-tracking potential ALS treatments, facilitating their availability. The region houses pharmaceutical and biotechnology companies specializing in neurological disorders, including ALS. Despite healthcare access challenges, North America generally offers good access to healthcare services, ensuring ALS patients receive necessary medical care and treatments.

Future Prospects and Conclusion

Despite challenges posed by the limited patient population, regulatory incentives, emerging therapies, and ongoing research hold promise for the ALS market. Continued innovations and investments in research and development are key to addressing the evolving needs of ALS patients globally.

This exhaustive report serves as an invaluable resource for stakeholders seeking comprehensive insights into ALS market dynamics, challenges, and opportunities shaping the landscape of ALS treatment development and patient care.

Some of the major companies operating in the Global Amyotrophic Lateral Sclerosis (ALS) Market include:

Sanofi S.A.
Brainstorm Cell Therapeutics Inc.
Biogen Inc.
Bausch Health Cos Inc.
F Hoffmann-la Roche Ltd
Ionis Pharmaceuticals
Mylan Pharma Inc.
Sun Pharmaceutical Industries Inc
Orion Pharma A/S
AB Science SA

Download Free Sample Report

Customers can also request 10% free customization on this report.

“Certain areas, particularly in North America, are projected to exert significant demand for the treatment of Amyotrophic Lateral Sclerosis (ALS). The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Amyotrophic Lateral Sclerosis (ALS) Market in the forecast period,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Amyotrophic Lateral Sclerosis (ALS) Market by Drug Type (Rilutek (Riluzole), Edaravone (Radicava)), By Treatment Type (Physical Therapy, Speech Therapy, Medication, Respiratory Therapy, Others), By End-Users (Hospitals & Clinics, Research and Academic institutes, others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Amyotrophic Lateral Sclerosis (ALS) Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Amyotrophic Lateral Sclerosis (ALS) Market.

Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=19774

Recently Published Report –

Amyotrophic Lateral Sclerosis (ALS) Market

Wolff Parkinson white syndrome Market

Respiratory Endotherapy Devices Market

Oxygen Filter Market

Women’s Health Market

Schizophrenia Drugs Market

Pseudomonas Aeruginosa Infection Treatment Market

LinkdedIn– https://www.linkedin.com/pulse/amyotrophic-lateral-sclerosis-als-market-rnabc/

Contact Techsci Research–

US –